Serum microRNA profiles as diagnostic biomarkers for HBV-positive hepatocellular carcinoma

Liver International

Volumn 37, Issue 6, 2017, Pages 888-896

  Zhu, Hao Tu ^a   Liu, Rong Bin ^a   Liang, Ya Yong ^b   Hasan, Abdulbaqi M E ^a   Wang, Hai Yun ^a   Shao, Qiong ^a   Zhang, Zi Chen ^a   Wang, Jing ^a   He, Cai Yun ^a   Wang, Fang ^a   Shao, Jian Yong ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

biomarkers; diagnosis; hepatocellular carcinoma; serum microRNA

Indexed keywords

ALPHA FETOPROTEIN; MICRORNA; MICRORNA 192 5P; MICRORNA 21 5P; MICRORNA 27A 3P; MICRORNA 27B 3P; MICRORNA 29A 3P; MICRORNA 30A 5P; MICRORNA 574 5P; MICRORNA LET 7C 5P; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; HEPATITIS B; HIGH THROUGHPUT SEQUENCING; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREDICTION; QUANTITATIVE ANALYSIS; RNA SEQUENCE; SEQUENCE ANALYSIS; UPREGULATION; BLOOD; CHINA; CHRONIC HEPATITIS B; COMPLICATION; GENETICS; HEPATITIS B VIRUS; LIVER TUMOR; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL; VIROLOGY;

ADULT; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHINA; FEMALE; GENE EXPRESSION PROFILING; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MICRORNAS; MIDDLE AGED; ROC CURVE;

EID: 85011649656     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13356     Document Type: Article

References (44)

1. Eggert T, McGlynn KA, Duffy A, et al. Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10. Gut. 2013;62:1667–1668.
2. Kamiyama T, Nakanishi K, Yokoo H, et al. Recurrence patterns after hepatectomy of hepatocellular carcinoma: implication of Milan criteria utilization. Ann Surg Oncol. 2009;16:1560–1571.
3. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.
4. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases(AASLD). Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236.
5. European Association for the Study of the Liver (EASL), European Organisation for Research and Treatment of Cancer (EORTC). EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.
6. Wong GL, Chan HL, Tse YK, et al. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology. 2014;59:986–995.
7. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–355.
8. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141:672–675.
9. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513–10518.
10. Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654–659.
11. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA. 2011;108:5003–5008.
12. Turchinovich A, Weiz L, Langheinz A, et al. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39:7223–7233.
13. Cermelli S, Ruggieri A, Marrero JA, et al. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One. 2011;6:e23937.
14. Chen YP, Jin X, Xiang Z, et al. Circulating MicroRNAs as potential biomarkers for alcoholic steatohepatitis. Liver Int. 2013a;33:1257–1265.
15. Chen YJ, Zhu JM, Wu H, et al. Circulating microRNAs as a fingerprint for liver cirrhosis. PLoS One. 2013b;8:e66577.
16. Li LM, Hu ZB, Zhou ZX, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 2010;70:9798–9807.
17. Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011;29:4781–4788.
18. Tomimaru Y, Eguchi H, Nagano H, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol. 2012;56:167–175.
19. Xu J, Wu C, Che X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog. 2011;50:136–142.
20. Zhang ZQ, Meng H, Wang N, et al. Serum microRNA143 and microRNA215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma. Diagn Pathol. 2014;9:135.
21. Morin RD, O'Connor MD, Griffith M, et al. Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. Genome Res. 2008;18:610–621.
22. Audic S, Claverie JM. The significance of digital gene expression profiles. Genome Res. 1997;7:986–995.
23. Blanco-Calvo M, Calvo L, Figueroa A, et al. Circulating microRNAs: molecular microsensors in gastrointestinal cancer. Sensors (Basel). 2012;12:9349–9362.
24. He Y, Huang C, Zhang SP, et al. The potential of microRNAs in liver fibrosis. Cell Signal. 2012;24:2268–2272.
25. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997–1006.
26. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS One. 2008;3:e3148.
27. Liu R, Chen X, Du Y, et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem. 2012;58:610–618.
28. Wang HY, Yan LX, Shao Q, et al. Profiling plasma microRNA in nasopharyngeal carcinoma with deep sequencing. Clin Chem. 2014;60:773–782.
29. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–422.
30. Leandro G, Zizzari S, Fabris C, et al. Do CA19-9 and TPA play a minor role as compared to AFP in diagnosing primary hepatocellular carcinoma? Oncology. 1989;46:381–385.
31. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998;27:273–278.
32. Oka H, Tamori A, Kuroki T, et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994;19:61–66.
33. Abdalla MA, Haj-Ahmad Y. Promising candidate urinary MicroRNA biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus egyptian patients. J Cancer. 2012;3:19–31.
34. Song P, Tobe RG, Inagaki Y, et al. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int. 2012;32:1053–1063.
35. Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta. 2008;395:19–26.
36. Zhao YJ, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma. Mol Clin Oncol. 2013;4:593–598.
37. Zhang S, Liu F, Mao X, et al. Elevation of miR-27b by HPV16 E7 inhibits PPARγ expression and promotes proliferation and invasion in cervical carcinoma cells. Int J Oncol. 2015;47:1759–1766.
38. Liu Y, Cai Q, Bao PP, et al. Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes. Breast Cancer Res Treat. 2015;152:183–191.
39. Zhuo L, Liu J, Wang B, et al. Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep. 2013;29:555–562.
40. Jin L, Wessely O, Marcusson EG, et al. Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNF-α in breast cancer. Cancer Res. 2013;73:2884–2896.
41. Kjersem JB, Ikdahl T, Lingjaerde OC, et al. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol Oncol. 2014;8:59–67.
42. Tan Y, Ge G, Pan T, et al. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One. 2014;9:e107986.
43. Roy S, Benz F, Alder J, et al. Down-regulation of miR-192-5p protects from oxidative stress-induced acute liver injury. Clin Sci (Lond). 2016;130:1197–1207.
44. Park G, Borkovich KA. Small RNA isolation and library construction for expression profiling of small RNAs from Neurospora and Fusarium using illumina high-throughput deep sequencing. Methods Mol Biol. 2012;883:155–164.